What is your presentation about?
The current advancements in obesity and diabetes pharmacotherapy allow us to move beyond a glucetric model for type 2 diabetes. We can now incorporate the intersections of weight loss and cardioprotection in our T2D treatments. I will review the current pharmacotherapy that promotes significant weight loss and reduction in blood glucose simultaneously.
What makes this topic important in 2022?
The parallel rise in T2D and obesity is a public health crisis. We must use all the tools available to not only do primary and secondary prevention of obesity and diabetes, but once a person suffers from obesity and T2D treat aggressively and work towards remission.
How did you become involved with this area of diabetes research or care?
I became passionate about T2D and obesity while working as an endocrinologist at the University of Alabama at Birmingham. I recognized it was critical to treat the intersections of obesity and T2D.
What are you most looking forward to at the 82nd Scientific Sessions?
The clinical sessions and reconnecting in person with colleagues.